Regeneron Pharmaceuticals, Inc. (REGN) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
REGN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
REGN Revenue Analysis (2014–2025)
As of March 2, 2026, Regeneron Pharmaceuticals, Inc. (REGN) generated trailing twelve-month (TTM) revenue of $14.34 billion, reflecting modest growth of +2.5% year-over-year. The most recent quarter (Q4 2025) recorded $3.88 billion in revenue, up 3.5% sequentially.
Looking at the longer-term picture, REGN's 5-year compound annual growth rate (CAGR) stands at +11.0%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $16.07 billion in 2021.
Revenue diversification analysis shows REGN's business is primarily driven by Collaboration Revenue (51%), Product (44%), and Product and Service, Other (5%). With over half of revenue concentrated in Collaboration Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including IMNM (-4.4% YoY), CLDX (-78.6% YoY), and RXRX (+27.5% YoY), REGN has underperformed the peer group in terms of revenue growth. Compare REGN vs IMNM →
Peer Comparison
Compare REGN's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| REGNCurrent | $14.3B | +2.5% | +11.0% | 25.7% | |
| IMNM | $9M | -4.4% | - | -3382.4% | |
| CLDX | $2M | -78.6% | -27.4% | -19160.0% | |
| RXRX | $75M | +27.5% | +85.4% | -867.9% | |
| NRIX | $84M | +54.0% | +36.3% | -340.2% | |
| ROIV | $29M | -56.4% | -15.6% | -3453.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $14.34B | +1.0% | $12.37B | 86.3% | $3.69B | 25.7% |
| 2024 | $14.20B | +8.3% | $12.23B | 86.1% | $3.99B | 28.1% |
| 2023 | $13.12B | +7.8% | $10.87B | 82.9% | $4.35B | 33.2% |
| 2022 | $12.17B | -24.3% | $10.47B | 86.0% | $5.39B | 44.2% |
| 2021 | $16.07B | +89.1% | $13.35B | 83.1% | $8.95B | 55.7% |
| 2020 | $8.50B | +29.6% | $7.14B | 84.0% | $3.58B | 42.1% |
| 2019 | $6.56B | -2.3% | $5.58B | 85.1% | $2.21B | 33.7% |
| 2018 | $6.71B | +14.3% | $6.13B | 91.3% | $2.53B | 37.8% |
| 2017 | $5.87B | +20.8% | $5.33B | 90.8% | $2.08B | 35.4% |
| 2016 | $4.86B | +18.4% | $4.46B | 91.7% | $1.33B | 27.4% |
See REGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs REGN Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare REGN vs AGIO
See how REGN stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is REGN's revenue growth accelerating or slowing?
REGN revenue growth slowed to +2.5%, below the 5-year CAGR of +11.0%. TTM revenue is $14.3B. The deceleration marks a shift from historical growth rates.
What is REGN's long-term revenue growth rate?
Regeneron Pharmaceuticals, Inc.'s 5-year revenue CAGR of +11.0% reflects the variable expansion pattern. Current YoY growth of +2.5% is near this long-term average.
How is REGN's revenue distributed by segment?
REGN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.